Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

930 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status.
Baldé A, Lang S, Wagner A, Ferrières J, Montaye M, Tattevin P, Cotte L, Aslangul E, Bidégain F, Chéret A, Mary-Krause M, Meynard JL, Molina JM, Partisani M, Roger PM, Boccara F, Costagliola D. Baldé A, et al. Among authors: molina jm. PLoS One. 2019 Jan 16;14(1):e0210253. doi: 10.1371/journal.pone.0210253. eCollection 2019. PLoS One. 2019. PMID: 30650119 Free PMC article.
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. Among authors: molina jm. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG. Soulié C, et al. Among authors: molina jm. AIDS. 2009 Jul 31;23(12):1605-8. doi: 10.1097/QAD.0b013e32832d9031. AIDS. 2009. PMID: 19487903 Clinical Trial.
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 study group. De Castro N, et al. Among authors: molina jm. Clin Infect Dis. 2009 Oct 15;49(8):1259-67. doi: 10.1086/605674. Clin Infect Dis. 2009. PMID: 19757993 Clinical Trial.
Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.
Rabian C, Tschöpe I, Lesprit P, Katlama C, Molina JM, Meynard JL, Delfraissy JF, Chêne G, Lévy Y; ANRS 114 Pneumovac Study Group. Rabian C, et al. Among authors: molina jm. Clin Infect Dis. 2010 Apr 15;50(8):1174-83. doi: 10.1086/651418. Clin Infect Dis. 2010. PMID: 20210645
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.
Lambert-Niclot S, Peytavin G, Duvivier C, Poirot C, Algarte-Genin M, Pakianather S, Meynard JL, Valantin MA, Molina JM, Flandre P, Katlama C, Calvez V, Marcelin AG. Lambert-Niclot S, et al. Among authors: molina jm. Antimicrob Agents Chemother. 2010 Nov;54(11):4910-3. doi: 10.1128/AAC.00725-10. Epub 2010 Aug 16. Antimicrob Agents Chemother. 2010. PMID: 20713677 Free PMC article. Clinical Trial.
930 results